Supplement to
4Q 2010
Earnings Release

Merck & Co., Inc.

Financial Highlights Package

Fourth Quarter 2010

Table of Contents

Table 1: GAAP P&L 1

Table 2a: GAAP to Non-GAAP P&L Reconciliation 4Q10 2

Table 2b: GAAP to Non-GAAP P&L Reconciliation Full Year 10 3

Table 2c: GAAP to Non-GAAP P&L Reconciliation 4Q09 4

Table 2d: GAAP to Non-GAAP P&L Reconciliation Full Year 09 5

Table 3: Sales – GAAP to Supplemental Combined Non-GAAP Reconciliation 4Q 6

Table 3a: Sales – GAAP to Supplemental Combined Non-GAAP Reconciliation Full Year 7

Table 3b: Sales – U.S. / Ex- U.S. Supplemental Combined Non-GAAP 4Q 8

Table 3c: Sales – U.S. / Ex- U.S. Supplemental Combined Non-GAAP Full Year 9

Table 3d: Sales – Human Health Geographic Split 10

Table 3e: Sales – GAAP Current Year by Quarter 11

Table 3f: Sales – Supplemental Combined Non-GAAP Prior Year by Quarter 12

Table 4: Equity Income / JV Sales / Other (Income) Expense 13

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1

	GAAP		% Change	GAAP		% Change
	4Q10	4Q09		Full Year 2010	Full Year 2009	
Sales	$ 12,094	$ 10,093	20%	$ 45,987	$ 27,428	68%
Costs, Expenses and Other						
Materials and production [1]	4,440	4,901	-9%	18,396	9,019	*
Marketing and administrative [1]	3,579	3,455	4%	13,245	8,543	55%
Research and development [1]	4,517	1,971	*	10,991	5,845	88%
Restructuring costs [2]	121	1,490	-92%	985	1,634	-40%
Equity income from affiliates [3]	(171)	(374)	-54%	(587)	(2,235)	-74%
Other (income) expense, net [4]	309	(7,813)	*	1,304	(10,668)	*
(Loss) Income Before Taxes	(701)	6,463	*	1,653	15,290	-89%
Income Tax (Benefit) Provision	(201)	(60)		671	2,268	
Net (Loss) Income	(500)	6,523	*	982	13,022	-92%
Less: Net Income Attributable to Noncontrolling Interests	31	29		121	123	
Net (Loss) Income Attributable to Merck & Co., Inc.	$ (531)	$ 6,494	*	$ 861	$ 12,899	-93%
(Loss) Earnings per Common Share Assuming Dilution [5]	$ (0.17)	$ 2.35	*	$ 0.28	$ 5.65	-95%
Average Shares Outstanding Assuming Dilution [6]	3,081	2,753		3,120	2,273	
Tax Rate [7]	28.7%	-0.9%		40.6%	14.8%	

*≥ 100%

(1) Amounts include the impact of purchase accounting adjustments, restructuring costs and merger-related costs. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities.

(3) In 2010, equity income from affiliates no longer reflects any contribution from the Merck/Schering-Plough partnership, which is now wholly-owned by the company as a result of the merger, or from Merial Limited due to the divesture of Merck's interest in September 2009.

(4) Other (income) expense, net in the fourth quarter and full year of 2010 includes $120 million and $200 million, respectively, of exchange losses due to Venezuelan currency devaluations. Other (income) expense, net for the full year of 2010 also includes a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca's exercise of the asset option. Other (income) expense, net in the fourth quarter of 2009 includes a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. In addition, other (income) expense, net for the full year of 2009 includes a $3.2 billion gain on the divestiture of Merck's interest in Merial Limited. Other (income) expense, net includes merger-related costs of $17 million for the full year of 2010 and $23 million and $173 million for the fourth quarter and full year of 2009, respectively.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders (losses are not allocated). Net income attributable to Merck & Co., Inc. common shareholders used to calculate earnings per common share assuming dilution was $6,463 million for the fourth quarter of 2009 and was $859 million and $12,853 million for the full year of 2010 and 2009, respectively.

(6) Because the company recorded a loss in the fourth quarter of 2010, no potential dilutive common shares were used in the computation of loss per share assuming dilution as the effect would have been anti-dilutive.

(7) The GAAP effective tax rates for the fourth quarter and full year of 2010 were 28.7% and 40.6%, respectively. Excluding the impact of the non-GAAP items detailed in the accompanying tables, the effective tax rates were 14.1% and 20.0% for the fourth quarter and full year of 2010, respectively. The fourth quarter and full year of 2010 GAAP and non-GAAP effective tax rates reflect a benefit of approximately $80 million as a result of the fourth quarter 2010 enactment of the tax extenders legislation, including the R&D tax credit.

The GAAP effective tax rates for the fourth quarter and full year of 2009 were (0.9)% and 14.8%, respectively. Excluding the impact of the non-GAAP items detailed in the accompanying tables, the effective tax rates were 15.3% and 20.0% for the fourth quarter and full year of 2009, respectively. The fourth quarter and full year of 2009 GAAP and non-GAAP effective tax rates were impacted by the favorable effect of tax settlements.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a

	GAAP	Purchase Accounting [1]	Restructuring Costs [2]	Merger-Related Costs [3]	Adjustment Subtotal	Non-GAAP
Sales	**$ 12,094**				$ -	$ 12,094
Materials and production	**4,440**	1,206	105		1,311	3,129
Marketing and administrative	**3,579**		13	160	173	3,406
Research and development	**4,517**	2,225	115		2,340	2,177
Restructuring costs	**121**		121		121	-
Equity income from affiliates	**(171)**				-	(171)
Other (income) expense, net	**309**				-	309
(Loss) Income Before Taxes	**(701)**	(3,431)	(354)	(160)	(3,945)	3,244
Income Tax (Benefit) Provision	**(201)**				(658) [4]	457
Net (Loss) Income	**(500)**				(3,287)	2,787
Less: Net Income Attributable to Noncontrolling Interests	**31**				-	31
Net (Loss) Income Attributable to Merck & Co., Inc.	**$ (531)**				$ (3,287)	$ 2,756
(Loss) Earnings per Common Share Assuming Dilution	**$ (0.17)**					$ 0.88 [5]
Average Shares Outstanding Assuming Dilution	**3,081**					3,106
Tax Rate	**28.7%**					14.1%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges, including a $1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Represents the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,746 million for the fourth quarter of 2010.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b

	GAAP	Purchase Accounting [1]	Restructuring Costs [2]	Merger-Related Costs [3]	Certain Other Items [4]	Adjustment Subtotal	Non-GAAP
Sales	**$ 45,987**					$ -	$ 45,987
Materials and production	**18,396**	6,566	430			6,996	11,400
Marketing and administrative	**13,245**		143	379		522	12,723
Research and development	**10,991**	2,441	428			2,869	8,122
Restructuring costs	**985**		985			985	-
Equity income from affiliates	**(587)**					-	(587)
Other (income) expense, net	**1,304**			17	507	524	780
Income Before Taxes	**1,653**	(9,007)	(1,986)	(396)	(507)	(11,896)	13,549
Taxes on Income	**671**					(2,042) [5]	2,713
Net Income	**982**					(9,854)	10,836
Less: Net Income Attributable to Noncontrolling Interests	**121**					-	121
Net Income Attributable to Merck & Co., Inc.	**$ 861**					$ (9,854)	$ 10,715
Earnings per Common Share Assuming Dilution	**$ 0.28**						$ 3.42 [6]
Average Shares Outstanding Assuming Dilution	**3,120**						3,120
Tax Rate	**40.6%**						20.0%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges, including a $1.7 billion charge to write-down the intangible asset related to vorapaxar.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca's exercise of the asset option.

(5) Includes a $391 million tax benefit from changes in a foreign entity's tax rate, a charge of $147 million associated with a change in tax law enacted as part of U.S. health care reform legislation, as well as the estimated tax impact on the other reconciling items.

6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $10,673 million for the full year of 2010.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2009
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c

	GAAP	Purchase Accounting [1]	Restructuring Costs [2]	Merger-Related Costs [3]	Certain Other Items [4]	Adjustment Subtotal	Non-GAAP
Sales	**$ 10,093**					$ -	$ 10,093
Materials and production	**4,901**	2,286	19			2,305	2,596
Marketing and administrative	**3,455**			265		265	3,190
Research and development	**1,971**		(13)			(13)	1,984
Restructuring costs	**1,490**		1,490			1,490	-
Equity income from affiliates	**(374)**					-	(374)
Other (income) expense, net	**(7,813)**			23	(7,930)	(7,907)	94
Income Before Taxes	**6,463**	(2,286)	(1,496)	(288)	7,930	3,860	2,603
Taxes on Income	**(60)**					(458) [5]	398
Net Income	**6,523**					4,318	2,205
Less: Net Income Attributable to Noncontrolling Interests	**29**					-	29
Net Income Attributable to Merck & Co., Inc.	**$ 6,494**					$ 4,318	$ 2,176
Earnings per Common Share Assuming Dilution	**$ 2.35**						$ 0.79 [6]
Average Shares Outstanding Assuming Dilution	**2,753**						2,753
Tax Rate	**-0.9%**						15.3%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. Also included in other (income) expense, net is $400 million of additional gain on the divesture of Merck's interest in Merial Limited which had been deferred.

(5) Represents the estimated tax impact on the reconciling items.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,166 million for the fourth quarter of 2009.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2009
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2d

	GAAP	Purchase Accounting [1]	Restructuring Costs [2]	Merger-Related Costs [3]	Certain Other Items [4]	Adjustment Subtotal	Non-GAAP
Sales	**$ 27,428**					$ -	$ 27,428
Materials and production	**9,019**	2,286	115			2,401	6,618
Marketing and administrative	**8,543**			371		371	8,172
Research and development	**5,845**		232			232	5,613
Restructuring costs	**1,634**		1,634			1,634	-
Equity income from affiliates	**(2,235)**					-	(2,235)
Other (income) expense, net	**(10,668)**			173	(10,692)	(10,519)	(149)
Income Before Taxes	**15,290**	(2,286)	(1,981)	(544)	10,692	5,881	9,409
Taxes on Income	**2,268**					390 [5]	1,878
Net Income	**13,022**					5,491	7,531
Less: Net Income Attributable to Noncontrolling Interests	**123**					-	123
Net Income Attributable to Merck & Co., Inc.	**$ 12,899**					$ 5,491	$ 7,408
Earnings per Common Share Assuming Dilution	**$ 5.65**						$ 3.25 [6]
Average Shares Outstanding Assuming Dilution	**2,273**						2,273
Tax Rate	**14.8%**						20.0%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested.

(3) Merger-related costs include transaction and integration costs associated with the merger.

(4) Included in other (income) expense, net is a $7.5 billion gain related to the Merck/Schering-Plough partnership recognized in connection with the merger. Also included in other (income) expense, net is a $3.2 billion gain on the divesture of Merck's interest in Merial Limited.

(5) Represents the estimated tax impact on the reconciling items.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $7,382 million for 2009.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2010
(AMOUNTS IN MILLIONS)
Table 3

The following Table reflects Supplemental Combined Non-GAAP sales for the prior year which were adjusted to reflect a full quarter of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	GAAP 4Q10	GAAP 4Q09	Adjustment 4Q09	Supp. Comb. Non-GAAP 4Q09	% Change (4Q10 GAAP vs Supp. Comb. Non-GAAP 4Q09)
TOTAL SALES [1]	**$12,094**	**$10,093**	**$2,123**	**$12,216**	**-1**
HUMAN HEALTH [2]	**10,581**	**9,072**	**1,733**	**10,805**	**-2**
Bone, Resp., Imm., & Dermatology					
Singulair	1,349	1,260		1,260	7
Remicade	710	431	205	635	12
Nasonex	303	165	121	286	6
Fosamax	234	285		285	-18
Clarinex	146	101	55	155	-6
Arcoxia	115	98		98	17
Proventil	55	26	30	56	-2
Asmanex	53	37	21	58	-8
Cardiovascular					
Zetia	629	399	215	614	2
Vytorin	562	384	194	577	-3
Integrilin	63	46	26	72	-12
Diabetes & Obesity					
Januvia	675	558		558	21
Janumet	288	202		202	42
Infectious Disease					
Isentress	313	234		234	34
PegIntron	198	149	67	216	-8
Cancidas	174	175		175	--
Primaxin	158	196		196	-19
Invanz	113	88		88	29
Avelox	92	66	52	118	-22
Rebetol	54	36	21	57	-4
Crixivan / Stocrin	58	52		52	11
Diversified Brands					
Cozaar / Hyzaar	415	955		955	-57
Zocor	121	139		139	-13
Propecia	124	123		123	1
Claritin Rx	122	71	38	109	11
Vasotec / Vaseretic	64	85		85	-25
Remeron	62	38	21	60	5
Proscar	44	72		72	-39
Neurosciences & Ophthalmology					
Maxalt	149	156		156	-5
Cosopt / Trusopt	131	134		134	-2
Subutex / Suboxone	1	36	20	56	-98
Oncology					
Temodar	266	188	103	292	-9
Emend	110	89		89	23
Caelyx	75	47	24	70	7
Intron A	54	38	16	54	-1
Vaccines					
ProQuad, M-M-R II and Varivax	285	333		333	-14
Gardasil	221	277		277	-20
RotaTeq	169	135		135	25
Pneumovax	156	128		128	22
Zostavax	107	76		76	41
Women's Health & Endocrine					
NuvaRing	145	88	47	135	7
Follistim AQ	138	96	53	149	-7
Implanon	71	37	16	53	34
Cerazette	49	35	18	53	-8
Other Human Health [3]	1,160	708	372	1,079	8
ANIMAL HEALTH	**815**	**494**	**265**	**759**	**7**
CONSUMER CARE [2]	**251**	**149**	**83**	**232**	**8**
Claritin OTC	67	39	25	63	6
Other Revenues [4]	**447**	**379**	**41**	**420**	**6**
Astra	302	332		332	-9

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $75 million and $50 million for fourth quarter 2010 and 2009, respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2010
(AMOUNTS IN MILLIONS)
Table 3a

The following Table reflects Supplemental Combined Non-GAAP sales for the prior year which were adjusted to reflect the period of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	GAAP Full Year 10	GAAP Full Year 09	Adjustment Full Year 09	Supp. Comb. Non-GAAP Full Year 09	% Change (FY 10 GAAP vs Supp. Comb. Non-GAAP FY 09)
TOTAL SALES [1]	**$45,987**	**$27,428**	**$18,537**	**$45,964**	**--**
HUMAN HEALTH [2]	**39,811**	**25,236**	**14,862**	**40,098**	**-1**
Bone, Resp., Imm., & Dermatology					
Singulair	4,987	4,660		4,660	7
Remicade	2,714	431	1,896	2,327	17
Nasonex	1,220	165	1,014	1,179	3
Fosamax	926	1,100		1,100	-16
Clarinex	659	101	619	719	-8
Arcoxia	398	358		358	11
Proventil	210	26	198	225	-7
Asmanex	208	37	177	214	-3
Cardiovascular					
Zetia	2,297	403	1,841	2,244	2
Vytorin	2,014	441	1,671	2,112	-5
Integrilin	266	46	249	295	-10
Diabetes & Obesity					
Januvia	2,385	1,922		1,922	24
Janumet	954	658		658	45
Infectious Disease					
Isentress	1,090	752		752	45
PegIntron	737	149	696	844	-13
Cancidas	611	617		617	-1
Primaxin	610	689		689	-11
Invanz	362	293		293	24
Avelox	316	66	302	368	-14
Rebetol	221	36	218	254	-13
Crixivan / Stocrin	206	206		206	--
Diversified Brands					
Cozaar / Hyzaar	2,104	3,561		3,561	-41
Zocor	468	558		558	-16
Propecia	447	440		440	1
Claritin Rx	420	71	362	433	-3
Vasotec / Vaseretic	255	311		311	-18
Remeron	223	38	195	234	-5
Proscar	216	291		291	-26
Neurosciences & Ophthalmology					
Maxalt	550	575		575	-4
Cosopt / Trusopt	484	503		503	-4
Subutex / Suboxone	111	36	175	211	-47
Oncology					
Temodar	1,065	188	885	1,073	-1
Emend	378	317		317	19
Caelyx	284	47	219	265	7
Intron A	209	38	192	231	-9
Vaccines					
ProQuad, M-M-R II and Varivax	1,378	1,369		1,369	1
Gardasil	988	1,118		1,118	-12
RotaTeq	519	522		522	-1
Pneumovax	376	346		346	9
Zostavax	243	277		277	-12
Women's Health & Endocrine					
NuvaRing	559	88	422	511	9
Follistim AQ	528	96	450	546	-3
Implanon	236	37	142	179	32
Cerazette	209	35	153	187	11
Other Human Health [3]	4,170	1,218	2,787	4,005	4
ANIMAL HEALTH	**2,941**	**494**	**2,222**	**2,716**	**8**
CONSUMER CARE [2]	**1,342**	**149**	**1,131**	**1,281**	**5**
Claritin OTC	401	39	367	406	-1
Other Revenues [4]	**1,893**	**1,548**	**322**	**1,870**	**1**
Astra	1,252	1,414		1,414	-11

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $282 million and $188 million for the full year 2010 and 2009, respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect the full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2010
(AMOUNTS IN MILLIONS)
Table 3b

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	Global			U.S.			International		
	4Q10	Supp. Comb. Non-GAAP 4Q09	% Change	4Q10	Supp. Comb. Non-GAAP 4Q09	% Change	4Q10	Supp. Comb. Non-GAAP 4Q09	% Change
TOTAL SALES [1]	**$12,094**	**$12,216**	**-1**	**$5,224**	**$5,535**	**-6**	**$6,870**	**$6,681**	**3**
HUMAN HEALTH [2]	**10,581**	**10,805**	**-2**	**4,400**	**4,740**	**-7**	**6,182**	**6,064**	**2**
Bone, Resp., Imm., & Dermatology									
Singulair	1,349	1,260	7	838	810	3	511	450	14
Remicade	710	635	12				710	635	12
Nasonex	303	286	6	146	157	-7	157	129	22
Fosamax	234	285	-18	25	39	-36	209	246	-15
Clarinex	146	155	-6	47	55	-14	99	100	-1
Arcoxia	115	98	17				115	98	17
Proventil	55	56	-2	53	54	-2	2	2	14
Asmanex	53	58	-8	47	55	-15	6	2	*
Cardiovascular									
Zetia	629	614	2	329	343	-4	299	271	10
Vytorin	562	577	-3	296	319	-7	266	258	3
Integrilin	63	72	-12	58	67	-14	5	5	9
Diabetes & Obesity									
Januvia	675	558	21	425	390	9	250	168	49
Janumet	288	202	42	164	136	21	123	66	86
Infectious Disease									
Isentress	313	234	34	164	113	45	149	121	23
PegIntron	198	216	-8	35	23	54	163	193	-16
Cancidas	174	175	--	17	19	-8	157	156	1
Primaxin	158	196	-19	29	41	-31	130	155	-16
Invanz	113	88	29	50	43	18	63	45	40
Avelox	92	118	-22	86	115	-25	6	4	79
Rebetol	54	57	-4				54	57	-4
Crixivan / Stocrin	58	52	11	2	2	-20	56	50	13
Diversified Brands									
Cozaar / Hyzaar	415	955	-57	9	363	-98	406	592	-31
Zocor	121	139	-13	12	10	18	109	129	-15
Propecia	124	123	1	39	38	3	85	84	1
Claritin Rx	122	109	11				122	109	11
Vasotec / Vaseretic	64	85	-25				64	85	-25
Remeron	62	60	5	1	3	-55	61	57	7
Proscar	44	72	-39	1	2	-27	43	71	-39
Neurosciences & Ophthalmology									
Maxalt	149	156	-5	106	107	-1	43	49	-12
Cosopt / Trusopt	131	134	-2	5	7	-24	126	127	-1
Subutex / Suboxone	1	56	-98				1	56	-98
Oncology									
Temodar	266	292	-9	109	103	7	157	189	-17
Emend	110	89	23	65	56	16	45	34	34
Caelyx	75	70	7				75	70	7
Intron A	54	54	-1	28	29	-4	26	25	2
Vaccines									
ProQuad, M-M-R II and Varivax	285	333	-14	272	310	-12	13	22	-43
Gardasil	221	277	-20	157	218	-28	64	59	8
RotaTeq	169	135	25	149	123	21	21	12	69
Pneumovax	156	128	22	115	74	56	40	54	-26
Zostavax	107	76	41	107	76	41			
Women's Health & Endocrine									
NuvaRing	145	135	7	86	80	8	58	55	5
Follistim AQ	138	149	-7	40	45	-10	98	105	-6
Implanon	71	53	34	24	18	36	47	36	33
Cerazette	49	53	-8				49	53	-8
Other Human Health [3]	1,160	1,079	8	263	297	-12	898	780	15
ANIMAL HEALTH	**815**	**759**	**7**	**169**	**161**	**5**	**646**	**598**	**8**
CONSUMER CARE [2]	**251**	**232**	**8**	**232**	**214**	**9**	**18**	**19**	**-2**
Claritin OTC	67	63	6	65	62	5	2	1	*
Other Revenues [4]	**447**	**420**	**6**	**423**	**420**	**1**	**24**		*****
Astra	302	332	-9	302	332	-9			

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $75 million and $50 million on a global basis for fourth quarter 2010 and 2009 respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

* 100% or over

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2010
(AMOUNTS IN MILLIONS)
Table 3c

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	Global			U.S.			International		
	Full Year 2010	Supp. Comb. Non-GAAP Full Year 2009	% Change	Full Year 2010	Supp. Comb. Non-GAAP Full Year 2009	% Change	Full Year 2010	Supp. Comb. Non-GAAP Full Year 2009	% Change
TOTAL SALES [1]	**$45,987**	**$45,964**	**--**	**$20,226**	**$21,269**	**-5**	**$25,761**	**$24,695**	**4**
HUMAN HEALTH [2]	**39,811**	**40,098**	**-1**	**16,811**	**17,766**	**-5**	**23,000**	**22,332**	**3**
Bone, Resp., Imm., & Dermatology									
Singulair	4,987	4,660	7	3,219	3,044	6	1,768	1,615	9
Remicade	2,714	2,327	17				2,714	2,327	17
Nasonex	1,220	1,179	3	639	648	-1	581	530	9
Fosamax	926	1,100	-16	93	161	-42	832	939	-11
Clarinex	659	719	-8	203	249	-19	457	470	-3
Arcoxia	398	358	11				398	358	11
Proventil	210	225	-7	202	220	-8	8	5	58
Asmanex	208	214	-3	195	204	-4	13	10	25
Cardiovascular									
Zetia	2,297	2,244	2	1,227	1,296	-5	1,070	948	13
Vytorin	2,014	2,112	-5	1,077	1,219	-12	938	893	5
Integrilin	266	295	-10	245	275	-11	20	19	5
Diabetes & Obesity									
Januvia	2,385	1,922	24	1,563	1,404	11	822	518	59
Janumet	954	658	45	576	472	22	378	187	*
Infectious Disease									
Isentress	1,090	752	45	554	370	50	536	382	40
PegIntron	737	844	-13	98	110	-11	639	735	-13
Cancidas	611	617	-1	61	73	-16	550	543	1
Primaxin	610	689	-11	123	136	-10	487	553	-12
Invanz	362	293	24	180	152	19	182	141	29
Avelox	316	368	-14	296	353	-16	20	15	36
Rebetol	221	254	-13	1	1	3	220	253	-13
Crixivan / Stocrin	206	206	--	8	10	-24	198	196	1
Diversified Brands									
Cozaar / Hyzaar	2,104	3,561	-41	400	1,321	-70	1,705	2,240	-24
Zocor	468	558	-16	42	45	-8	426	513	-17
Propecia	447	440	1	148	148	--	298	293	2
Claritin Rx	420	433	-3				420	433	-3
Vasotec / Vaseretic	255	311	-18				255	311	-18
Remeron	223	234	-5	7	10	-31	216	224	-4
Proscar	216	291	-26	6	6	1	210	285	-26
Neurosciences & Ophthalmology									
Maxalt	550	575	-4	378	398	-5	173	176	-2
Cosopt / Trusopt	484	503	-4	20	39	-50	464	464	
Subutex / Suboxone	111	211	-47				111	211	-47
Oncology									
Temodar	1,065	1,073	-1	403	387	4	662	686	-3
Emend	378	317	19	230	202	14	147	115	28
Caelyx	284	265	7				284	265	7
Intron A	209	231	-9	114	121	-6	95	110	-13
Vaccines									
ProQuad, M-M-R II and Varivax	1,378	1,369	1	1,305	1,288	1	73	81	-9
Gardasil	988	1,118	-12	722	802	-10	266	317	-16
RotaTeq	519	522	-1	439	468	-6	81	54	49
Pneumovax	376	346	9	296	245	21	80	101	-21
Zostavax	243	277	-12	243	277	-12			
Women's Health & Endocrine									
NuvaRing	559	511	9	342	313	9	217	198	10
Follistim AQ	528	546	-3	167	179	-6	361	368	-2
Implanon	236	179	32	86	63	38	150	116	29
Cerazette	209	187	11				209	187	11
Other Human Health [3]	4,170	4,005	4	903	1,057	-15	3,266	2,947	11
ANIMAL HEALTH	**2,941**	**2,716**	**8**	**616**	**599**	**3**	**2,326**	**2,117**	**10**
CONSUMER CARE [2]	**1,342**	**1,281**	**5**	**1,213**	**1,175**	**3**	**128**	**105**	**22**
Claritin OTC	401	406	-1	379	390	-3	23	16	45
Other Revenues [4]	**1,893**	**1,870**	**1**	**1,586**	**1,729**	**-8**	**307**	**141**	*****
Astra	1,252	1,414	-11	1,252	1,414	-11			

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $282 million and $188 million on a global basis for full year 2010 and 2009, respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

* 100% or over

MERCK & CO., INC.
HUMAN HEALTH GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
Table 3d

	1Q10	2Q10	3Q10	4Q10	Full Year
TOTAL HUMAN HEALTH	**$9,793**	**$9,776**	**$9,660**	**$10,581**	**$39,811**
United States	**4,090**	**4,041**	**4,281**	**4,400**	**16,811**
% Human Health Sales	41.8%	41.3%	44.3%	41.6%	42.2%
Europe (1)	**2,831**	**2,660**	**2,360**	**2,690**	**10,541**
% Human Health Sales	28.9%	27.2%	24.4%	25.4%	26.5%
Japan	**811**	**902**	**855**	**1,077**	**3,645**
% Human Health Sales	8.3%	9.2%	8.9%	10.2%	9.2%
Latin America	**694**	**728**	**742**	**819**	**2,983**
% Human Health Sales	7.1%	7.4%	7.7%	7.7%	7.5%
Asia Pacific	**587**	**659**	**659**	**755**	**2,659**
% Human Health Sales	6.0%	6.7%	6.8%	7.1%	6.7%
Eastern Europe/Middle East Africa	**404**	**422**	**371**	**410**	**1,607**
% Human Health Sales	4.1%	4.3%	3.8%	3.9%	4.0%
Canada	**337**	**328**	**374**	**364**	**1,403**
% Human Health Sales	3.4%	3.4%	3.9%	3.4%	3.5%
Other	**39**	**37**	**17**	**67**	**161**
% Human Health Sales	0.4%	0.4%	0.2%	0.6%	0.4%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
Full Year 2010
(AMOUNTS IN MILLIONS)
Table 3e

	2010 - GAAP				
	1Q	2Q	3Q	4Q	Full Year
TOTAL SALES [1]	**$11,422**	**$11,346**	**$11,125**	**$12,094**	**$45,987**
HUMAN HEALTH [2]	**9,793**	**9,776**	**9,660**	**10,581**	**39,811**
Bone, Resp., Imm., & Dermatology					
Singulair	1,165	1,258	1,215	1,349	4,987
Remicade	674	669	661	710	2,714
Nasonex	320	338	259	303	1,220
Fosamax	230	241	220	234	926
Clarinex	174	202	137	146	659
Arcoxia	95	95	94	115	398
Proventil	57	55	43	55	210
Asmanex	51	56	48	53	208
Cardiovascular					
Zetia	534	564	571	629	2,297
Vytorin	477	490	485	562	2,014
Integrilin	70	70	63	63	266
Diabetes & Obesity					
Januvia	511	600	600	675	2,385
Janumet	201	218	247	288	954
Infectious Disease					
Isentress	232	267	278	313	1,090
PegIntron	186	185	168	198	737
Cancidas	153	150	135	174	611
Primaxin	159	158	135	158	610
Invanz	75	83	91	113	362
Avelox	106	59	59	92	316
Rebetol	56	55	55	54	221
Crixivan / Stocrin	52	48	49	58	206
Diversified Brands					
Cozaar / Hyzaar	782	485	423	415	2,104
Zocor	116	117	114	121	468
Propecia	100	113	109	124	447
Claritin Rx	124	93	81	122	420
Vasotec / Vaseretic	59	63	69	64	255
Remeron	51	59	50	62	223
Proscar	58	56	58	44	216
Neurosciences & Ophthalmology					
Maxalt	135	133	133	149	550
Cosopt / Trusopt	115	123	114	131	484
Subutex / Suboxone	52	51	7	1	111
Oncology					
Temodar	274	271	254	266	1,065
Emend	84	93	91	110	378
Caelyx	74	66	70	75	284
Intron A	54	51	50	54	209
Vaccines					
ProQuad, M-M-R II and Varivax	319	340	434	285	1,378
Gardasil	233	219	316	221	988
RotaTeq	93	139	119	169	519
Pneumovax	51	59	110	156	376
Zostavax	95	18	23	107	243
Women's Health & Endocrine					
NuvaRing	135	145	134	145	559
Follistim AQ	134	137	119	138	528
Implanon	51	51	64	71	236
Cerazette	55	49	56	49	209
Other Human Health [3]	974	986	1,049	1,160	4,170
ANIMAL HEALTH	**709**	**731**	**687**	**815**	**2,941**
CONSUMER CARE [2]	**379**	**422**	**291**	**251**	**1,342**
Claritin OTC	110	132	92	67	401
Other Revenues [4]	**542**	**417**	**487**	**447**	**1,893**
Astra	364	241	345	302	1,252

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $55 million, $57 million, $94 million and $75 million for the first, second, third and fourth quarters of 2010, respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP
FULL YEAR 2009
(AMOUNTS IN MILLIONS)
Table 3f

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters and a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	2009 - Supplemental Combined Non-GAAP				
	1Q	2Q	3Q	4Q	Full Year
TOTAL SALES [1]	**$10,683**	**$11,534**	**$11,531**	**$12,216**	**$45,964**
HUMAN HEALTH [2]	9,235	9,956	10,101	10,805	40,098
Bone, Resp., Imm., & Dermatology					
Singulair	1,057	1,257	1,085	1,260	4,660
Remicade	518	565	608	635	2,327
Nasonex	306	321	266	286	1,179
Fosamax	261	277	276	285	1,100
Clarinex	174	226	164	155	719
Arcoxia	81	88	90	98	358
Proventil	54	56	59	56	225
Asmanex	49	54	53	58	214
Cardiovascular					
Zetia	510	556	563	614	2,244
Vytorin	477	532	525	577	2,112
Integrilin	76	73	74	72	295
Diabetes & Obesity					
Januvia	411	462	491	558	1,922
Janumet	128	155	173	202	658
Infectious Disease					
PegIntron	216	215	198	216	844
Isentress	148	172	197	234	752
Primaxin	165	160	168	196	689
Cancidas	139	149	155	175	617
Avelox	109	71	70	118	368
Invanz	62	71	73	88	293
Rebetol	66	67	64	57	254
Crixivan / Stocrin	49	56	49	52	206
Diversified Brands					
Cozaar / Hyzaar	839	906	861	955	3,561
Zocor	137	141	141	139	558
Propecia	103	106	109	123	440
Claritin Rx	132	96	95	109	433
Vasotec / Vaseretic	77	76	73	85	311
Proscar	72	79	67	72	291
Remeron	50	50	74	60	234
Neurosciences & Ophthalmology					
Maxalt	133	141	144	156	575
Cosopt / Trusopt	121	125	123	134	503
Subutex / Suboxone	50	52	53	56	211
Oncology					
Temodar	247	256	278	292	1,073
Emend	69	77	82	89	317
Caelyx	61	68	67	70	265
Intron A	54	67	56	54	231
Vaccines					
ProQuad, M-M-R II and Varivax	252	322	462	333	1,369
Gardasil	262	268	311	277	1,118
RotaTeq	134	126	127	135	522
Pneumovax	41	47	130	128	346
Zostavax	75	42	84	76	277
Women's Health & Endocrine					
Follistim AQ	131	145	122	149	546
NuvaRing	115	129	131	135	511
Cerazette	39	46	49	53	187
Implanon	37	43	45	53	179
Other Human Health [3]	945	965	1,016	1,079	4,005
ANIMAL HEALTH	**621**	**672**	**664**	**759**	**2,716**
CONSUMER CARE [2]	**384**	**381**	**283**	**232**	**1,281**
Claritin OTC	149	108	85	63	406
Other Revenues [4]	**443**	**524**	**483**	**420**	**1,870**
Astra	356	386	340	332	1,414

[1] Only select products are shown.

[2] Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

[3] Includes Human Health products not individually shown above. Other Vaccines sales included in Other Human Health were $50M in 1Q09, $34M in 2Q09, $54M in 3Q09, and $50M in 4Q09, respectively.

[4] Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP
FOURTH QUARTER 2010

Table 4

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	4Q10	4Q09	FY 2010	FY 2009
ASTRAZENECA LP	$ 190	$ 192	$ 546	$ 674
MERCK / SCHERING-PLOUGH [1]	-	151	-	1,195
Other [2]	(19)	31	41	366
TOTAL	$ 171	$ 374	$ 587	$ 2,235

[1] Upon completion of the merger with Schering-Plough, the Merck/Schering-Plough partnership became wholly-owned by the company.

[2] Primarily reflects results for Merial Limited (which was disposed of on September 17, 2009), Sanofi Pasteur MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

	4Q10	4Q09	FY 2010	FY 2009
GARDASIL	$ 106	$ 132	$ 350	$ 549
FLU VACCINES	62	82	220	249
OTHER VIRAL VACCINES	27	33	93	112
ROTATEQ	9	13	42	42
HEPATITIS VACCINES	7	9	25	44
Other Vaccines	135	167	487	593
TOTAL SANOFI PASTEUR MSD SALES	$ 346	$ 436	$ 1,217	$ 1,589

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q10	4Q09	FY 2010	FY 2009
INTEREST INCOME	$ (27)	$ (11)	$ (83)	$ (210)
INTEREST EXPENSE	177	169	715	460
EXCHANGE LOSSES (GAINS)	130	(9)	214	(12)
Other, net [1]	29	(7,962)	458	(10,906)
TOTAL	$ 309	$ (7,813)	$ 1,304	$ (10,668)

[1] Other, net for the full year of 2010 primarily reflects a $950 million legal reserve and a $443 million gain recognized upon AstraZeneca's exercise of the asset option. Other, net for the fourth quarter and full year of 2009 primarily reflects a $7.5 billion gain associated with the Merck/Schering-Plough partnership. In addition, the full year of 2009 also reflects a $3.2 billion gain on the sale of Merck's interest in Merial Limited.